Home NDC 0074-2625-01 Mavyret
Product NDC 0074-2625
Requested package NDC 0074-2625-01
11-digit product format 000742625
Labeler code 0074
Product ID 0074-2625_2c392930-500d-4e9b-93ac-317c4d48251c
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name Glecaprevir and Pibrentasvir
Dosage form TABLET, FILM COATED
Route ORAL
Labeler AbbVie Inc.
Application NDA209394
Marketing category NDA
Marketing start 2017-08-03
Substance GLECAPREVIR; PIBRENTASVIR
Active strength 100; 40 mg/1; mg/1
Pharmacologic classes Breast Cancer Resistance Protein Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], HCV NS3/4A Protease Inhibitors [MoA], Hepatitis C Virus NS3/4A Protease Inhibitor [EPC], Hepatitis C Virus NS5A Inhibitor [EPC], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], UGT1A1 Inhibitors [MoA], UGT1A1 Inhibitors [MoA]
NDC exclude flag No
Listing certified through 2027-12-31
Current FDA listing Yes Observed NDC auxiliary status history# This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.
Historic NDC status page 1 of 1 · 2 matching rows.
View current auxiliary records. · View the auxiliary file history.
Captured / source date, Dataset, Scope table Captured / source date Dataset Scope Product NDC Package NDC Code Status Reporting period Archive Snapshot Source SHA-256 2025-12-14 17:58 UTC · source 2025-12-05 excluded package package 0074-2625 0074-2625-01 D Discontinued by firm excluded / ndc_excluded.zip d630ba8d3edf…732f749b63fb…2025-08-27 00:01 UTC · source 2025-08-26 excluded package package 0074-2625 0074-2625-01 D Discontinued by firm excluded / ndc_excluded.zip f5e01cc5f278…a2eaf40c39c3…
Source provenance: Browse the complete Orange Book source catalog · source snapshot 1 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N209394-001 MAVYRET GLECAPREVIR; PIBRENTASVIR 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03
Orange Book patents# Current patent rows page 1 of 1 · 30 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N209394-001 10028937 2030-06-10 U-2141 2018-08-24 N209394-001 10028937 2030-06-10 U-3237 2018-08-24 N209394-001 10028937 2030-06-10 U-4206 2018-08-24 N209394-001 10039754 2030-06-10 U-2141 2018-09-06 N209394-001 10039754 2030-06-10 U-3237 2018-09-06 N209394-001 10039754 2030-06-10 U-4206 2018-09-06 N209394-001 9586978 2030-11-06 U-2141 2017-08-29 N209394-001 9586978 2030-11-06 U-3237 2017-08-29 N209394-001 9586978 2030-11-06 U-4206 2017-08-29 N209394-001 10028937*PED 2030-12-10 Pediatric extension N209394-001 10039754*PED 2030-12-10 Pediatric extension N209394-001 9586978*PED 2031-05-06 Pediatric extension N209394-001 8648037 2032-01-19 U-2141 Drug substance, Drug product 2017-08-29 N209394-001 8648037 2032-01-19 U-3237 Drug substance, Drug product 2017-08-29 N209394-001 8648037 2032-01-19 U-4206 Drug substance, Drug product 2017-08-29 N209394-001 8937150 2032-05-18 Drug substance, Drug product 2017-08-29 N209394-001 8648037*PED 2032-07-19 Pediatric extension N209394-001 8937150*PED 2032-11-18 Pediatric extension N209394-001 10286029 2034-03-14 U-3237 2019-05-31 N209394-001 10286029 2034-03-14 U-4206 2019-05-31 N209394-001 11484534 2034-03-14 U-3237 2022-11-30 N209394-001 11484534 2034-03-14 U-4206 2022-11-30 N209394-001 10286029*PED 2034-09-14 Pediatric extension N209394-001 11484534*PED 2034-09-14 Pediatric extension N209394-001 RE48923 2035-05-08 Drug substance 2022-03-08 N209394-001 9321807 2035-06-05 Drug substance 2017-08-29 N209394-001 RE48923*PED 2035-11-08 Pediatric extension N209394-001 9321807*PED 2035-12-05 Pediatric extension N209394-001 11246866 2036-06-24 Drug product 2022-03-08 N209394-001 11246866*PED 2036-12-24 Pediatric extension
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 7 matching rows.
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 2 · 41 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-02-19 14:30 UTC 2026-02 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 8072bd15b7f6…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 5c6f7cd8ea54…2022-04-08 23:34 UTC 2022-04 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 5d02ea3f76ae…2022-04-04 05:41 UTC 2022-04 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 4b0b4de00fa7…2019-12-13 00:20 UTC 2019-12 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 74a2ff9319b5…2022-03-09 01:35 UTC 2022-03 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 bb7c543d1eb4…2021-12-28 21:50 UTC 2021-12 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 782e0a99824c…2021-05-05 16:15 UTC · 3 captures of this ZIP 2021-05 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 87673890dc5c…2021-03-12 10:30 UTC 2021-03 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 5aa47cf7b7d7…2020-12-22 03:56 UTC 2020-12 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 8869cabd3fbd…2020-11-12 02:37 UTC 2020-11 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 c0c555d07b60…2019-12-14 00:12 UTC 2019-12 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 3f01610625f2…2019-09-15 20:21 UTC 2019-09 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 b00525d2431f…2019-07-19 19:46 UTC 2019-07 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 ea99ee380514…2024-03-16 18:09 UTC · 4 captures of this ZIP 2024-03 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 6a51e52b5d6a…2024-02-18 07:12 UTC 2024-02 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 1c564ffb4f44…2023-12-20 04:57 UTC 2023-12 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 ea1830bbd6c7…2023-11-28 05:40 UTC · 2 captures of this ZIP 2023-11 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 a72a2bbeb626…2023-10-25 00:34 UTC · 2 captures of this ZIP 2023-10 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 9b2671bbb829…2023-07-15 15:27 UTC · 2 captures of this ZIP 2023-07 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 a67488948f0b…2023-06-13 01:57 UTC · 3 captures of this ZIP 2023-06 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 3f0d92c62455…2023-05-13 08:27 UTC 2023-05 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 053a50430f4f…2023-01-26 05:58 UTC 2023-01 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 3bdfa0b2c4d7…2022-11-12 20:34 UTC · 5 captures of this ZIP 2022-11 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 3a93d1ddd44b…2022-10-28 04:53 UTC 2022-10 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N209394-001 MAVYRET 100MG;40MG TABLET / ORAL RLD, RS 2017-08-03 cb3db0bc1861…
Observed Orange Book patent history# Patent history page 1 of 22 · 879 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-02-19 14:30 UTC 2026-02 N209394-001 10028937 2030-06-10 U-4206 2018-08-24 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 10028937 2030-06-10 U-2141 2018-08-24 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 10028937 2030-06-10 U-3237 2018-08-24 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 10039754 2030-06-10 U-2141 2018-09-06 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 10039754 2030-06-10 U-4206 2018-09-06 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 10039754 2030-06-10 U-3237 2018-09-06 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 9586978 2030-11-06 U-4206 2017-08-29 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 9586978 2030-11-06 U-3237 2017-08-29 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 9586978 2030-11-06 U-2141 2017-08-29 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 10028937*PED 2030-12-10 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 10039754*PED 2030-12-10 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 9586978*PED 2031-05-06 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 8648037 2032-01-19 U-2141 Drug substance, Drug product 2017-08-29 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 8648037 2032-01-19 U-4206 Drug substance, Drug product 2017-08-29 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 8648037 2032-01-19 U-3237 Drug substance, Drug product 2017-08-29 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 8937150 2032-05-18 Drug substance, Drug product 2017-08-29 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 8648037*PED 2032-07-19 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 8937150*PED 2032-11-18 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 10286029 2034-03-14 U-4206 2019-05-31 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 10286029 2034-03-14 U-3237 2019-05-31 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 11484534 2034-03-14 U-4206 2022-11-30 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 11484534 2034-03-14 U-3237 2022-11-30 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 10286029*PED 2034-09-14 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 11484534*PED 2034-09-14 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 RE48923 2035-05-08 Drug substance 2022-03-08 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 9321807 2035-06-05 Drug substance 2017-08-29 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 RE48923*PED 2035-11-08 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 9321807*PED 2035-12-05 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 11246866 2036-06-24 Drug product 2022-03-08 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209394-001 11246866*PED 2036-12-24 Pediatric extension 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N209394-001 10028937 2030-06-10 U-4206 2018-08-24 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N209394-001 10028937 2030-06-10 U-2141 2018-08-24 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N209394-001 10028937 2030-06-10 U-3237 2018-08-24 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N209394-001 10039754 2030-06-10 U-2141 2018-09-06 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N209394-001 10039754 2030-06-10 U-4206 2018-09-06 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N209394-001 10039754 2030-06-10 U-3237 2018-09-06 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N209394-001 9586978 2030-11-06 U-4206 2017-08-29 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N209394-001 9586978 2030-11-06 U-3237 2017-08-29 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N209394-001 9586978 2030-11-06 U-2141 2017-08-29 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N209394-001 10028937*PED 2030-12-10 Pediatric extension 31067a03dcf5…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 9 · 355 observed states.
Additional Listing Data#
Finished product Yes
Brand name base Mavyret
Listing expiration 2027-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength PIBRENTASVIR 100 mg/1 GLECAPREVIR 40 mg/1
Harmonized UNII identifiers# UNII identifiers page 1 of 1 · 2 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 2WU922TK3L Internal UNII lookup K6BUU8J72P Internal UNII lookup
Harmonized RxCUI identifiers# RxCUI identifiers page 1 of 1 · 4 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 1940703 Internal RxNorm lookup 1940709 Internal RxNorm lookup 2557906 Internal RxNorm lookup 2557910 Internal RxNorm lookup
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
DailyMed Product Concepts# DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 0074-2625-01 Mavyret 1 in 1 CARTON TABLET, FILM COATED 1 200 0074-2625-01 Mavyret 3 in 1 DOSE PACK TABLET, FILM COATED 3 200 0074-2625-04 Mavyret 4 in 1 CARTON TABLET, FILM COATED 4 200 0074-2625-04 Mavyret 7 in 1 CARTON TABLET, FILM COATED 7 200 0074-2625-28 Mavyret 7 in 1 CARTON TABLET, FILM COATED 7 200 0074-2625-28 Mavyret 4 in 1 CARTON TABLET, FILM COATED 4 200 0074-2625-56 Mavyret 4 in 1 CARTON TABLET, FILM COATED 4 200 0074-2625-56 Mavyret 2 in 1 CARTON TABLET, FILM COATED 2 200 0074-2625-80 Mavyret 84 in 1 BOTTLE TABLET, FILM COATED 84 200 0074-2625-84 Mavyret 84 in 1 BOTTLE TABLET, FILM COATED 84 200
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 0074-2625 MAVYRET (GLECAPREVIR AND PIBRENTASVIR) TABLET, FILM COATED MAVYRET (GLECAPREVIR AND PIBRENTASVIR) PELLET [ABBVIE INC.] 197 Current NDC, Legacy NDC, 10 package rows 20250425_7bf99777-0401-9095-8645-16c6e907fcc0.zip
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Marketing end Sample Exclude flag Status 0074-2625-01 00074262501 1 DOSE PACK in 1 CARTON (0074-2625-01) > 3 TABLET, FILM COATED in 1 DOSE PACK 1 dose pack 2017-08-03 0000-00-00 No No Current